A common constipation drug shows surprising power to protect kidneys

Researchers have identified an unexpected application for lubiprostone, a medication commonly prescribed for chronic constipation, which may help slow the progression of chronic kidney disease (CKD). Findings from a clinical trial involving 150 patients indicate that the drug helped preserve kidney function in individuals diagnosed with moderate CKD, a condition that frequently progresses toward kidney failure and the need for dialysis.

The results, reported on May 8, 2026, suggest a complex biological link between the gastrointestinal system and renal health. While lubiprostone was originally developed to increase intestinal fluid secretion to treat constipation, the trial observed a secondary effect that mitigated the decline of glomerular filtration rates in the study participants.

The Role of the Gut-Kidney Axis

Scientists investigating the mechanism behind this effect focused on the gut-kidney axis, a bidirectional communication system where the health of the intestinal microbiome influences systemic inflammation and organ function. The researchers found that lubiprostone induced specific changes in the composition and activity of gut bacteria.

These microbial shifts led to an increased production of spermidine, a naturally occurring polyamine. Spermidine is recognized in medical research for its ability to promote autophagy, the process by which cells clear out damaged components to maintain internal stability.

The increase in spermidine levels appeared to provide a protective effect on the mitochondria within kidney cells. Mitochondria serve as the primary energy producers for the cell, and their dysfunction is a known driver of cellular damage and fibrosis in the kidneys of patients with CKD.

Impact on Chronic Kidney Disease Progression

Chronic kidney disease is a progressive condition characterized by the gradual loss of kidney function. Moderate CKD typically refers to stages where the kidneys are still functioning but are significantly less efficient at filtering waste and excess fluids from the blood.

Without effective intervention, many patients with moderate CKD eventually transition to end-stage renal disease. At this stage, the kidneys can no longer support the body’s needs, necessitating renal replacement therapies such as hemodialysis or kidney transplantation.

By stabilizing mitochondrial health through the spermidine pathway, lubiprostone appeared to reduce the rate of kidney damage in the trial cohort. This suggests that pharmacological interventions targeting the gut microbiome could offer a new strategy for managing renal decline.

Pharmacology and Repurposing

The use of lubiprostone for kidney preservation is an example of drug repurposing, where a medication approved for one condition is found to be effective for another. Lubiprostone works as a chloride channel activator, specifically targeting the CIC-2 channels in the intestinal epithelium.

The trial’s discovery that a chloride channel activator could influence the production of polyamines like spermidine highlights the interconnected nature of human physiology. It indicates that the systemic effects of a drug can extend far beyond its primary target organ.

This finding aligns with growing interest in personalized medicine, where treatments are tailored based on a patient’s specific biological markers, such as their microbiome composition or mitochondrial efficiency.

Limitations and Future Research

Despite the promising results, researchers emphasize that the study was limited to a small group of 150 patients. Larger, multi-center randomized controlled trials are necessary to confirm these findings across more diverse populations and to determine the optimal dosage for renal protection.

Further investigation is also required to understand if the protective effects of lubiprostone are consistent across different stages of kidney disease or if they are specific to the moderate stage. Scientists seek to determine if supplementing spermidine directly, rather than using a drug to stimulate its production via gut bacteria, would yield similar results.

Medical professionals caution that lubiprostone is not currently approved for the treatment of chronic kidney disease, and patients should not use the medication for this purpose without professional medical supervision.

• The trial involved 150 patients with moderate CKD.
• Lubiprostone was found to preserve kidney function by altering gut microbiota.
• The mechanism involves the increased production of spermidine.
• Spermidine supports mitochondrial health, reducing cellular damage in the kidneys.
• The findings suggest a potential new pathway for slowing the progression toward dialysis.